Pharvaris N.V. Overview
Pro stress-test →Pharvaris N.V. is a late-stage biopharmaceutical company focusing on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapy to prevent and treat angioedema attacks.
Strategic Profile
Pro stress-test →Pharvaris is developing deucrictibant, a novel, potent, oral small-molecule bradykinin B2 receptor antagonist with two distinct formulations to address unmet needs in both on-demand (immediate-release capsule) and prophylactic (extended-release tablet) hereditary angioedema treatment. Expected pivotal readouts include CHAPTER-3 in H2 2026 and RAPIDe-3 in Q4 2025, with a validated kinin assay for biomarker measurement.
Competitive Landscape
Pro stress-test →Key competitors in the bradykinin-mediated angioedema space include Xenon Pharmaceuticals, KalVista Pharmaceuticals, and Upstream Bio. Pharvaris differentiates through dual-formulation oral approach targeting both prophylactic and on-demand treatment paradigms, distinguishing from existing injectable therapies.
Industry Context
Pharvaris N.V. operates in Biopharmaceuticals - Rare Diseases / Specialty Care.
Key facts
Founded: 2015 · Headquarters: Zug, Switzerland · Market cap: $1.1B